AU2001258536A1 - Derivatisation of proteins in aqueous solution - Google Patents

Derivatisation of proteins in aqueous solution

Info

Publication number
AU2001258536A1
AU2001258536A1 AU2001258536A AU5853601A AU2001258536A1 AU 2001258536 A1 AU2001258536 A1 AU 2001258536A1 AU 2001258536 A AU2001258536 A AU 2001258536A AU 5853601 A AU5853601 A AU 5853601A AU 2001258536 A1 AU2001258536 A1 AU 2001258536A1
Authority
AU
Australia
Prior art keywords
derivatization
groups
denaturant
vivo
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258536A
Inventor
Gregory Gregoriadis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipoxen Technologies Ltd
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Publication of AU2001258536A1 publication Critical patent/AU2001258536A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Proteins are derivitized by reaction of pendant groups, usually groups which are side chains in non-terminal amino acyl units of the protein, in aqueous reactions in the presence of a denaturant. The denaturant is preferably an amphiphilic compound, most preferably an anionic amphiphilic compound such as a long chain alkyl sulphate mono ester, preferably an alkaline metal salt, for instance sodium dodecyl sulphate. The degree of derivatization is increased, while the protein retains activity, such as enzyme activity. The increase in the degree of derivatization enhances the increase in circulation time in vivo and stability on storage and in vivo. Preferably the derivatizing reagent is an aldehyde compound which reacts with primary amine groups, generally the epsilon-amino group of lysyl units. Derivatization is conducted under reducing conditions to generate a secondary amine derivative.
AU2001258536A 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution Abandoned AU2001258536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00304108.4 2000-05-16
EP00304108 2000-05-16
PCT/GB2001/002115 WO2001087922A2 (en) 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution

Publications (1)

Publication Number Publication Date
AU2001258536A1 true AU2001258536A1 (en) 2001-11-26

Family

ID=8172993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258536A Abandoned AU2001258536A1 (en) 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution

Country Status (8)

Country Link
US (1) US6962972B2 (en)
EP (1) EP1335931B1 (en)
JP (1) JP2003533537A (en)
AT (1) ATE313554T1 (en)
AU (1) AU2001258536A1 (en)
DE (1) DE60116137T2 (en)
ES (1) ES2256234T3 (en)
WO (1) WO2001087922A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
ES2294535T3 (en) 2003-08-12 2008-04-01 Lipoxen Technologies Limited DERIVATIVES OF POLISIALIC ACID.
WO2006016168A2 (en) 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives
JP5026266B2 (en) 2004-08-12 2012-09-12 リポクセン テクノロジーズ リミテッド Separation
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
CN101160326B (en) 2005-02-23 2013-04-10 利普生技术有限公司 Activated sialic acid derivatives for protein derivatisation and conjugation
EP2041167B1 (en) * 2006-07-25 2010-05-12 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
EP2409995A3 (en) 2007-02-28 2012-08-15 Lipoxen Technologies Limited Reduction of endotoxin in polysialic acids
PL2459224T3 (en) * 2009-07-27 2017-08-31 Baxalta GmbH Blood coagulation protein conjugates
NZ597600A (en) * 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
KR102172133B1 (en) 2010-07-30 2020-11-02 박스알타 인코퍼레이티드 Nucleophilic catalysts for oxime linkage
EP3412314A1 (en) 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
SI2717898T1 (en) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
WO2013106787A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
RS63870B1 (en) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
KR102403545B1 (en) 2012-07-11 2022-05-30 바이오버라티브 테라퓨틱스 인크. Factor viii complex with xten and von willebrand factor protein, and uses thereof
SG10201913738YA (en) 2013-06-28 2020-03-30 Bioverativ Therapeutics Inc Thrombin cleavable linker with xten and its uses thereof
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
HUE057005T2 (en) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
CN117106095A (en) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 Factor VIII chimeric proteins and uses thereof
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
MA40524A (en) 2014-09-26 2021-03-17 Bayer Pharma AG STABILIZED ADRENOMEDULLINE DERIVATIVES AND THEIR USE
EP3207130B1 (en) 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
TWI741992B (en) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 Factor ix fusion proteins and methods of making and using same
AU2016362606A1 (en) 2015-12-03 2018-06-28 Takeda Pharmaceutical Company Limited Factor VIII with extended half-life and reduced ligand-binding properties
MA45473A (en) 2016-04-04 2019-02-13 Shire Human Genetic Therapies CONJUGATE C1 ESTERASE INHIBITOR AND ITS USES
CA3094112A1 (en) 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
JP2021523878A (en) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド How to treat hemophilia A
BR112020026512A2 (en) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company FGF-21 FORMULATIONS
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process

Also Published As

Publication number Publication date
DE60116137D1 (en) 2006-01-26
ATE313554T1 (en) 2006-01-15
WO2001087922A2 (en) 2001-11-22
DE60116137T2 (en) 2006-08-24
EP1335931A2 (en) 2003-08-20
US20030129159A1 (en) 2003-07-10
ES2256234T3 (en) 2006-07-16
WO2001087922A3 (en) 2003-05-30
JP2003533537A (en) 2003-11-11
EP1335931B1 (en) 2005-12-21
US6962972B2 (en) 2005-11-08

Similar Documents

Publication Publication Date Title
AU2001258536A1 (en) Derivatisation of proteins in aqueous solution
Jahngen-Hodge et al. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress
Scaduto Jr Oxidation of DMSO and methanesulfinic acid by the hydroxyl radical
MA23825A1 (en) SYNTHESIS OF BLEACHING ACTIVATORS
EA199900980A1 (en) IMPROVED WAYS TO PREPARE ACTIVATED PROTEIN C
ATE219380T1 (en) VEHICLES FOR INTRODUCING NUCLEIC ACIDS INTO CELLS
ES2152813B1 (en) OPEN CELL POLYURETHANE CELLULAR PRODUCTS.
ES2136418T3 (en) DETERMINATION OF GLYCOSILATED PROTEINS.
ES2076398T3 (en) PROCEDURE FOR THE PREPARATION OF L-ORNITHINE SALTS.
BR0002854A (en) Animal food supplements containing aqueous lysine and process for their production
ATE227705T1 (en) GUANIDINYLATION REAGENT
Ranieri-Raggi et al. Effects of storage on activity and subunit structure of rabbit skeletal-muscle AMP deaminase.
BR9712575A (en) Process for restoring cells that have a mutated p53 protein, a p53-dependent transactivation activity, uses a single chain antibody capable of specifically binding a mutated p53 protein, and a coding nucleic acid, molecule 11d3 or a variant, nucleic acid and composition
Elliott et al. Relationship between a tumor promoter-induced decrease in queuine modification of transfer RNA in normal human cells and the expression of an altered cell phenotype
HIGASHI et al. Re-evaluation of protein-bound glutathione in rat liver
NO20003880L (en) Transfectants which are sensitive to reducing conditions, pharmaceutical preparations containing them and their uses
Kulmacz Concerted loss of cyclooxygenase and peroxidase activities from prostaglandin H synthase upon proteolytic attack
EP1474526A4 (en) Enzyme activation protease assay
PT979036E (en) ENZYMATIC CONCENTRATE
KUBOTA et al. Carboxypeptidases from the exocarp of mandarin orange (Citrus unshiu MARC.). II. Chemical and enzymatic properties of carboxypeptidases Cua and Cub
Strom et al. Enoyl coenzyme A reduction by bovine mammary fatty acid synthetase. Specificity and other characteristics.
NOMURA et al. Effect of modification of sulfhydryl groups in soybean β-amylase on the interaction with substrate and inhibitors
García-Carreño et al. Control of digestive functions in shrimp, I. An inhibitor of trypsin activity in the hepatopancreas
林征一 et al. Biochemical properties of glutamate dehydrogenase purified from eel liver.
Moos et al. Relationship between molecular conversions of acrosin and the progression of exocytosis in the calcium ionophore-induced acrosome reaction